Skip to content
Get the Balanced News app for a better experience!
The Balanced News Logo
Analytics
The Balanced News Logo

Stay Balanced, Stay Informed

Menu
  • Browse News
  • Underreported Stories
  • Curated Feeds
  • Insights
  • Analytics
  • Our Writers
  • About Us
  • Download App
Learn
  • How It Works
  • Bias Detection
  • Lens Score
  • Source Bias Checker
  • Accountability
  • Custom Feeds
Newsroom
  • Writers & Analysts
  • About TBN
  • Editorial Standards
  • Corrections Policy
  • Our Partners
  • Insights
Socials
  • Youtube
  • Instagram
  • X
  • Facebook
News Categories
  • Trending
  • Politics
  • Sports
  • Business
  • Tech
  • Entertainment
  • Health
  • Science
  • Crime
  • Lifestyle
  • National
  • International
  • Good News
  • Crypto

Get Our App

Available for iOS and Android


LensFeedsInsightsAnalyticsTrendingGood NewsSportsPoliticsBusinessCrimeTechEntertainmentHealthNationalInternational

© 2026 The Balanced News. All rights reserved.

About UsEditorial StandardsCorrectionsHelp & SupportPrivacy PolicyTerms & Conditions
Symbiotec Pharmalab Raises Rs 526 Crore from Anchor Investors Ahead of Rs 1,757 Crore IPO

Categories

Categories

Related Coverage

Select a news story to see related coverage from other media outlets.

Related Coverage

Select a news story to see related coverage from other media outlets.

  1. Home
  2. /
  3. Business

Symbiotec Pharmalab Raises Rs 526 Crore from Anchor Investors Ahead of Rs 1,757 Crore IPO

Analysed 21 Aug 2026·5 sources analysed·Vadodara, India·Business
Symbiotec Pharmalab Raises Rs 526 Crore from Anchor Investors Ahead of Rs 1,757 Crore IPOPreviousNext

Symbiotec Pharmalab is launching its initial public offering (IPO) from August 24 to 27, aiming to raise Rs 1,757 crore at a price band of Rs 938-988 per share. The IPO includes a fresh issue of Rs 150 crore and an offer for sale of Rs 1,607 crore by promoters and investors. The company raised Rs 526 crore from 34 anchor investors, including mutual funds, insurance companies, and foreign portfolio investors. Proceeds from the fresh issue will be used for debt repayment and general corporate purposes.

Sentiment
51%
TBN's observations

First-hand measurement across 5 sources

We measured how 5 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (51/100). Lens Score 55/100.

Outlets measured: businessstandard, economictimes, moneycontrol, news18, mint. See how each one headlined and framed the same story in the source comparison below.

AI analysis of 5 sources · Published under editorial oversight by The Balanced News
Analysed 21 Aug 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Sentiment — Neutral (51/100)

Sentiment was consistent across outlets (50–52/100), indicating broadly factual reporting rather than editorialising.

Coverage timeline

mint broke this story on 21 Aug, 02:17 pm. Other outlets followed.

21 Aug, 02:17 pm5 sources · 2 h21 Aug, 04:31 pm
AI analysis by the TBN Bias Engine · beat methodology byMrunal Wange· Business & Economy Editor· editorial standards byOjas Kale
← Previous
Reserve Bank of India Announces Premature Redemption Dates for Sovereign Gold Bonds
Next →
Sarbananda Sonowal Inaugurates Rs 428 Crore Projects, Signs Rs 1,580 Crore Deals at Paradip Port
  1. 1
    mint21 Aug, 02:17 pm
    Symbiotec Pharmalab IPO: Price band, lot size, GMP, listing date and other key details Stock Market News
  2. 2
    news1821 Aug, 03:18 pm
    Symbiotec Pharmalab raises Rs 526 cr from anchor investors; IPO opens on Aug 24
  3. 3
    moneycontrol21 Aug, 03:44 pm
    Symbiotec Pharmalab raises over Rs 526 crore from 34 anchor investors ahead of Rs 1,757-crore IPO- Moneycontrol.com
  4. 4
    economictimes21 Aug, 04:04 pm
    Symbiotec Pharmalab gets Rs 526 crore anchor backing ahead of IPO; Citi Group, Singularity among investors
  5. 5
    businessstandard21 Aug, 04:31 pm
    Symbiotec Pharmalab raises 526 cr from anchor investors; IPO opens Aug 24

Who's involved

Institutions and figures named across source coverage.

Corporate
MUFG Intime India Private LimitedSatwani HoldingsTata Mutual FundMotilal Oswal Investment AdvisorsIndia Business Excellence Fund-IIIHDFC Mutual FundICICI Prudential Asset Management CompanyBNP ParibasCitigroup Global MarketsBharti AXA Life InsuranceAvendus CapitalNomura FinancialIndia Business Excellence Fund IIIMirae AssetRosewood InvestmentsBajaj Life InsuranceEdelweiss Mutual FundITI Mutual FundSymbiotec PharmalabBNP Paribas Financial MarketsGroww Mutual FundMotilal Oswal Mutual FundJM FinancialCitigroup Global Markets MauritiusSatwani Holdings Limited Liability PartnershipMotilal OswalSingularity Asset Management CompanyTIMF HoldingsSymbiotec Pharmalab LimitedSusquehanna PacificTata AIA Life InsuranceICICI Prudential Mutual FundEdelweissMotilal Oswal Asset Management CompanyNomura Financial Advisory and Securities India

Story context

Category
Business
Location
Vadodara, India
Sources analysed
5
Last analysed
21 Aug 2026
Key entities
Initial public offeringCroreIndian rupeeIndiaPharmaceutical industryBiotechnologyNational Stock Exchange of IndiaActive ingredientMutual fundTata GroupCommon stockCitigroup